Modulation of seizures and synaptic plasticity by adenosinergic receptors in an experimental model of temporal lobe epilepsy induced by pilocarpine in rats

Epilepsia

Volumn 46, Issue SUPPL. 5, 2005, Pages 166-173

  Vianna, Eduardo Paulo Morowsky ^a   Ferreira, Alice Teixeira ^a   Doná, Flávia ^a   Cavalheiro, Esper Abrão ^a   Fernandes, Maria José Da Silva ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adenosine receptors; Ecto 5 nucleotidase; Pilocarpine model; Status epilepticus; Temporal lobe epilepsy

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 3,7 DIMETHYL 1 PROPARGYLXANTHINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5 PHENYLACETYLAMINO 1,2,4 TRIAZOLO[1,5 C]QUINAZOLINE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR; CONVULSANT AGENT; ECTO 5' NUCLEOTIDASE; NEUROPROTECTIVE AGENT; PHENYLISOPROPYLADENOSINE; PILOCARPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; APOPTOSIS; CONFERENCE PAPER; ENZYME ACTIVITY; EPILEPSY; EPILEPTIC STATE; EXPERIMENTAL MODEL; HIPPOCAMPUS; MALE; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE; TEMPORAL LOBE EPILEPSY;

EID: 21844471509     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2005.01027.x     Document Type: Conference Paper

References (64)

1. Abbracchio MP, Cattabeni F. Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases. Ann N Y Acad Sci 1999;890:79-92.
2. Zimmermann H, Braun N. Ecto-nucleotidases: molecular structures, catalytic properties, and functional roles in the nervous system. Prog Brain Res 1999;120:371-85.
3. Schoen SW, Kreutzberg GW. Evidence that 5′-nucleotidase is associated with malleable synapses: an enzyme cytochemical investigation of olfactory bulb of adult rats. Neuroscience 1995;65:37-50.
4. Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 2001;24:31-55.
5. Fastbom J, Pazos A, Palacios JM. The distribution of adenosine A1 receptors and 5′nucleotidase in the brain of some commonly used experimental animals. Neuroscience 1987;22:813-26.
6. Thompson SM, Haas HL, Gahwiller BH. Comparison of the actions of adenosine at pre and postsynaptic receptors in the rat hippocampus in vitro. J Physiol 1992;451:347-63.
7. Dunwiddie TV. The physiological role of adenosine in the central nervous system. Int Rev Neurobiol 1985;27:63-139.
8. Dunwiddie TV. Adenosine and suppression of seizures. Adv Neurol 1999;79:1001-10.
9. Fredholm BB, Dunwiddie TV. How does adenosine inhibit transmitter release? Trends Pharmacol 1988;9:130-4.
10. Jarvis MF, Williams M. Direct autoradiographic localization of adenosine A2 receptors in the rat brain using A2-selective agonist, [3H]CGS 21680. Eur J Pharmacol 1989;168:243-6.
11. Weiss SM, Benwell K, Cliffe IA, et al. Discovery of nonxanthine adenosine A2a receptor antagonists for the treatment of Parkinson's disease. Neurology 2003;61:S101-6.
12. Cunha RA, Johansson B, Van Der Ploeg I, et al. Evidence for functionally important adenosine A2a receptor in the rat hippocampus. Brain Res 1994;649:208-16.
13. Lopes LV, Cunha RA, Ribeiro JA. Crosstalk between A1 and A2a adenosine receptors in the hippocampus and cortex of young adult and aged rats. J Neurophysiol 1999;82:3196-203.
14. Cunha RA, Ribeiro JA. Adenosine A2a receptor facilitation of synaptic transmission in the CA1 area of the rat hippocampus requires protein kinase C but not protein kinase A activation. Neurosci Lett 2000;289:127-30.
15. Richardson PJ, Cunha RA. Extracellular metabolism and function of purines in immunoisolated cholinergic nerve terminals. Neurochem Int 1992;21(suppl):Q10.
16. Sebastião AM, Ribeiro JA. A2 receptor mediated excitatory actions of adenosine in the nervous system. Prog Neurobiol 1996;48:167-89.
17. von Lubitz DK, Lin RC, Popik P, et al. Adenosine A3 receptor stimulation and cerebral ischemia. Eur J Pharmacol 1994;263:59-67.
18. Dunwiddie TV, Diao L, Kim HO, et al. Activation of hippocampal adenosine 3 receptors produces a heterologous desensitization of Al receptor mediated responses in rat hippocampus. J Neurosci 1997;17:607-14.
19. Etherington LAV, Frenguelli BG. Endogenous adenosine modulates epileptiform activity in rat hippocampus in a receptor subtype-dependent manner. Eur J Neurosci 2004;19:2539-50.
20. During MJ, Spencer DD. Adenosine: a potential mediator of seizure arrest and postictal refractoriness. Ann. Neurol 1992;32:618-24.
21. George B, Kulkarni SK. Modulation of lithium-pilocarpine-induced status epilepticus by adenosinergic agents. Methods Find Exp Clin Pharmacol 1997;19:329-33.
22. Khan GM, Smolders I, Ebinger G, et al. Anticonvulsant effect and neurotransmitter modulation of focal and systemic 2-chloroadenosine against the development of pilocarpine-induced seizures. Neuropharmacology 2000;39:2418-32.
23. Gouder N, Fritschy JM, Boison D. Seizure suppression by adenosine A1 receptor activation in a mouse model of pharmacoresistant epilepsy. Epilepsia 2003;44:877-85.
24. Dragunow M. Adenosine and epileptic seizure. In: Phillis JW, ed. Adenosine and adenine nucleotides as regulators of cellular function. Boca Raton: CRC Press; 1991:367-79.
25. Cavalheiro EA. Pilocarpine model of epilepsy. Ital J Neurol Sci 1995;16:33-7.
26. Mello LEAM, Cavalheiro EA, Tan AM, et al. Granule cell dispersion in relation to mossy fiber sprouting, hippocampal cell loss, silent period and seizure frequency in the pilocarpine model of epilepsy. aIn: Engel J Jr, Wasterlain C, Cavalheiro EA, et al, eds. Molecular neurobiology of epilepsy. Amsterdam: Elsevier; 1992:51-61.
27. Turski WA, Cavalheiro EA, Schwarz M, et al. Limbic seizures produced by pilocarpine in rats: behavioural, electroencephalographic and neuropathological study. Behav Brain Res 1983;9:315-35.
28. Leite JP, Bortolotto ZA, Cavalheiro EA. Spontaneous recurrent seizures in rats: an experimental model of partial epilepsy. Neurosci Biobehav Rev 1990;14:511-7.
29. Cavalheiro EA, Calderazzo-Filho LS, Bortolotto ZA, et al. Anticonvulsant role of adenosine. Pol J Pharmacol 1987;39:537-44.
30. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. Sydney: Academic; 1986.
31. Abercrombie M. Estimation of nuclear population from microtome sections. Anat Rec 1946;94:239-47.
32. Bailly YL, Schoen SW, Mariani J, et al. Immature chemodifferentiation of Purkinje cell synapses revealed by 5′nucleotidase ectoenzyme activity in the cerebellum of the reeler mouse. Synapse 1998;29:279-92.
33. Rebola N, Coelho JE, Costenla AR, et al. Decrease of adenosine A1 receptor density and of adenosine neuromodulation in the hippocampus of kindled rats. Eur J Neurosci 2003;18:820-8.
34. Jones PA, Smith RA, Stone TW. Protection against kainite-induced excitotoxicity by adenosine A2a receptor agonists and antagonists. Neuroscience 1998;85:229-37.
35. MacGregor DG, Jones PA, Maxwell WL, et al. Prevention by a purine analogue of kainite-induced neuropathology in rat hippocampus. Brain Res 1996;725:115-20.
36. Brundege JM, Dunwiddie TV. Role of adenosine as a modulator of synaptic activity in the central nervous system. Adv Pharmacol 1997;39:353-91.
37. Moreau JL, Huber G. Central adenosine A2a receptors: an overview. Brain Res Rev 1999;31:65-82.
38. Mendonça A, Sebastião AM, Ribeiro JA. Adenosine does it have a neuroprotective role after all? Brain Res Rev 2000;33:258-74.
39. Chen JF, Huang Z, Ma J, et al. A2a adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 1999;19:9192-200.
40. Sebastiao AM, Ribeiro JA. Fine-tuning neuromodulation by adenosine. Trends Pharmacol Sci 2000;21:341-6.
41. Monopoli A, Lozza G, Forlani A, et al. Blockade of adenosine A2a receptors results in neuroprotective effects in cerebral ischemia in rats. Neuroreport 1998;9:3955-9.
42. Schwarzchild MA, Xu K, Oztas E, et al. Neuroprotection by caffeine and more specific A2a receptor antagonists in animal models of Parkinson's disease. Neurology 2003;61:S55-61.
43. Huber A, Guttinger M, Mohler H, et al. Seizure suppression by adenosine A2a receptor activation in a rat model of audiogenic brainstem epilepsy. Neurosci Lett 2002;329:289-92.
44. Zhang JM, Wang HK, Ye CQ, et al. Activation of adenosine A1 receptors underlies anticonvulsant effect of CGS21680. Eur J Pharmacol 1994;255:239-43.
45. 3H]GABA release from rat hippocampal nerve terminals. Neuropharmacology 2000;39:1156-67.
46. Rebola N, Pinheiro PC, Oliveira CR, et al. Subcellular localization of adenosine A1 receptors in nerve terminals and synapses of the rat hippocampus. Brain Res 2003;987:49-58.
47. Popoli P, Pintor A, Domenici MR, et al. Blockade of adenosine A2a receptors reduces, through a pre-synaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J Neurosci 2002;22:1967-75.
48. Bona E, Adén U, Giland E, et al. Neonatal cerebral hypoxia-ischemia: the effect of adenosine receptor antagonists. Neuropharmacology 1997;36:1327-38.
49. Ongini E, Schubert P. Neuroprotection induced by stimulating A1 or blocking A2a adenosine receptors: an apparent paradox. Drug Dev Res 1998;45:387-93.
50. Nehlig A, Daval JL, Boyet S. Effects of selective adenosine A1 and A2 receptor agonists and antagonists on local rates of energy metabolism in the rat brain. Eur J Pharmacol 1994;258:57-66.
51. Fernandes MJS, Dubé C, Boyet S, et al. Correlation between hyper metabolism and neuronal damage during status epilepticus induced by lithium and pilocarpine in immature and adult rats. J Cereb Blood Flow Metab 1999;19:195-209.
52. Ceruti S, Barbieri D, Franceschi C, et al. Effects of adenosine A3 receptor agonists on astrocytes: induction of cell protection at low and cell death at high concentrations. Drug Dev Res 1996;3: 177.
53. von Lubitz DKJE, Lin RCS, Boyd M, et al. Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: neuronal and glial effects. Eur J Pharmacol 1999;367:157-63.
54. Sajjadi FG, Takabayashi K, Foster AC, et al. Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. J Immunol 1996;156:3435-42.
55. Lehtimaki KA, Peltola J, Koskikallio E, et al. Expression of cytokines and cytokine receptors in the rat brain after kainic-induced seizures. Brain Res Mol Brain Res 2003;110:253-60.
56. Vezzani A, Moneta D, Richichi C, et al. Functional role of inflammatory cytokines and anti-inflammatory molecules in seizures and epileptogenesis. Epilepsia 2002;43(suppl 5):30-5.
57. Shandra AA, Godlevsky LS, Vastyanov RS, et al. The role of TNF-alpha in amygdale kindled rats. Neurosci Res 2002;42:147-53.
58. De Simoni MG, Perego C, Ravizza T, et al. Inflammatory cytokines and related genes are induced in the rat hippocampal limbic status epilepticus. Eur J Neurosci 2000;12:2623-33.
59. Meli DN, Loeffler JM, Baumann P, et al. In pneumococcal meningitis a novel water-soluble inhibitor of matrix metalloproteinases and TNF-alpha converting enzyme attenuates seizure injury of the cerebral cortex. J Neuroimmunol 2004;151:6-11.
60. Jacobson KA, Park KS, Jiang JL, et al. Pharmacological characterization of novel A3 adenosine receptor-selective antagonists. Neuropharmacology 1997;36:1157-65.
61. Bonan CD, Walz R, Pereira GS, et al. Changes in synaptosomal ectonucleotidase activities in two rat models of temporal lobe epilepsy. Epilepsy Res 2000;39:229-38.
62. Wierazko A, Seyfried TN. ATP-induced synaptic potentiation in hippocampal slices. Brain Res 1989;491:356-9.
63. Banati RB, Gerhmann J, Schubert P, et al. Cytotoxicity of microglia. Glia 1993;7:111-8.
64. Vianna EPM, Ferreira AT, Naffah-Mazzacoratti MG, et al. Evidence that ATP participates in the pathophysiology of pilocarpine-induced temporal lobe epilepsy: fluorimetric, immunohistochemical and Western blot studies. Epilepsia 2002;43(suppl 5):227-9.